AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2679035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroprusside at an initial rate of 1 microgram/kg/min
Number of subjects: 120
Study 2679035 — intervention group
Group type: COMPARATOR
Intervention: No vasodilator (Control)
Number of subjects: 120
Study 905083 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (treatment)
Number of subjects: 72
Study 905083 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 30010835 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to a customized evidence‐based nutrition website in addition to standard care.
Number of subjects: 250
Study 30010835 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 250
Study 28464810 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital P.A.R.T.Y.
Number of subjects: 953
Study 28464810 — intervention group
Group type: EXPERIMENTAL
Intervention: On-base P.A.R.T.Y.
Number of subjects: 953
Study 28464810 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine ADF annual alcohol awareness training)
Number of subjects: 953
Study 28464810 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 953
Study 25998035 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-month evidence-based performance review intervention with resources to support practice change
Number of subjects: 165
Study 25998035 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 165
Study 23666440 — intervention group
Group type: EXPERIMENTAL
Intervention: Store and forward teledermatology
Number of subjects: 261
Study 23666440 — intervention group
Group type: COMPARATOR
Intervention: Conventional consultation
Number of subjects: 261
Study 21922125 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry Fundamentals™ CD‐ROM
Number of subjects: 39
Study 21922125 — intervention group
Group type: COMPARATOR
Intervention: Control practices (no intervention)
Number of subjects: 39
Study 19726772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg extended-release once daily)
Number of subjects: 497
Study 19726772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 17923351 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3902 (rolofylline)
Number of subjects: 32
Study 17923351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15110307 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture embedded seeds
Number of subjects: 8
Study 15110307 — intervention group
Group type: COMPARATOR
Intervention: Loose seeds
Number of subjects: 8
Study 11576006 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPP adult health educator intervention curriculum
Number of subjects: 4001
Study 11576006 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual health education curriculum)
Number of subjects: 4001
Study 9623181 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive eradication of Helicobacter pylori in patients on omeprazole
Number of subjects: 0
Study 9623181 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole therapy
Number of subjects: 0
Study 7880985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralphate suspension (1 g/5 ml)
Number of subjects: 16
Study 7880985 — intervention group
Group type: COMPARATOR
Intervention: Sucralphate tablet (1 g)
Number of subjects: 16
Study 2740067 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide alone (regimen A)
Number of subjects: 80
Study 2740067 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide in combination with low-dose chlorpromazine and high-dose hydrocortisone (regimen B)
Number of subjects: 80
Study 31784236 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Ankle Instability (CAI) group
Number of subjects: 32
Study 31784236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 31564831 — intervention group
Group type: EXPERIMENTAL
Intervention: IR‐ESO (esomeprazole 20 mg/sodium bicarbonate 800 mg)
Number of subjects: 40
Study 31564831 — intervention group
Group type: COMPARATOR
Intervention: ESO (esomeprazole 20 mg)
Number of subjects: 40
Study 31564831 — intervention group
Group type: EXPERIMENTAL
Intervention: IR‐ESO
Number of subjects: 40
Study 31564831 — intervention group
Group type: COMPARATOR
Intervention: ESO
Number of subjects: 40
Study 31564831 — intervention group
Group type: EXPERIMENTAL
Intervention: IR‐ESO and ESO
Number of subjects: 40
Study 27215561 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI) counseling
Number of subjects: 0
Study 27215561 — intervention group
Group type: COMPARATOR
Intervention: Standardized positive prevention counseling alone
Number of subjects: 0
Study 25359409 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial mouthwash (3-day use)
Number of subjects: 15
Study 25359409 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 15
Study 23225338 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted CBT
Number of subjects: 176
Study 23225338 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 176
Study 21224870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (daily 2000 IU) for 10 weeks
Number of subjects: 32
Study 21224870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21224870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (daily 2000 IU)
Number of subjects: 32
Study 21224870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (daily 2000 IU) and Placebo
Number of subjects: 32
Study 19882059 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose paracetamol (40 mg/kg orally)
Number of subjects: 72
Study 19882059 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume)
Number of subjects: 72
Study 17589374 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based counseling and STI management with free male condoms
Number of subjects: 172
Study 15499651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autotransfusion (IAT)
Number of subjects: 81
Study 15499651 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion (HBT)
Number of subjects: 81
Study 11565628 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment (n = 11) for 2 weeks
Number of subjects: 20
Study 11565628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9) for 2 weeks
Number of subjects: 20
Study 9732308 — intervention group
Group type: EXPERIMENTAL
Intervention: D-tagatose
Number of subjects: 8
Study 9732308 — intervention group
Group type: COMPARATOR
Intervention: sucrose
Number of subjects: 8
Study 8152898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 615
Study 8152898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 3162901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoxacin 200 mg
Number of subjects: 8
Study 3162901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoxacin 800 mg
Number of subjects: 8
Study 3162901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enoxacin 200 mg
Number of subjects: 8
Study 3162901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enoxacin 800 mg
Number of subjects: 8
Study 31004814 — intervention group
Group type: EXPERIMENTAL
Intervention: 3–4 weeks postpartum appointment
Number of subjects: 364
Study 31004814 — intervention group
Group type: EXPERIMENTAL
Intervention: 6–8 weeks postpartum appointment
Number of subjects: 364
Study 31004814 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study sample
Number of subjects: 364
Study 31004814 — intervention group
Group type: EXPERIMENTAL
Intervention: 3–4 weeks group
Number of subjects: 364
Study 31004814 — intervention group
Group type: EXPERIMENTAL
Intervention: 6–8 weeks group
Number of subjects: 364
Study 29543134 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 8 weeks
Number of subjects: 20
Study 29543134 — intervention group
Group type: COMPARATOR
Intervention: Sham training control
Number of subjects: 20
Study 26593781 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced sun protection intervention (sunscreen pre-application/reapplication; protective hats and clothing; use of shade)
Number of subjects: 4347
Study 26593781 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 4347
Study 25187755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 289
Study 25187755 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 50 μg/kg
Number of subjects: 289
Study 23106879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasma vaporization of the prostate (BPVP)
Number of subjects: 30
Study 18975258 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 27
Study 18975258 — intervention group
Group type: COMPARATOR
Intervention: Control (no RMT)
Number of subjects: 27
Study 17180485 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk drink supplemented with whey peptides (125 ml every morning for 12 weeks)
Number of subjects: 54
Study 17180485 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 54
Study 17180485 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk drink supplemented with whey peptides
Number of subjects: 54
Study 15539863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 18
Study 15539863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 18
Study 15539863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 40 mg
Number of subjects: 18
Study 15539863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 80 mg
Number of subjects: 18
Study 15539863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 18
Study 15539863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11241439 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation (CS)
Number of subjects: 25
Study 11241439 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 25
Study 9738312 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorized participants under high task or situational uncertainty
Number of subjects: 0
Study 9738312 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification with minimal in-group
Number of subjects: 0
Study 9738312 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem as a derivative motive
Number of subjects: 0
Study 7780297 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-link mapping counseling strategy
Number of subjects: 0
Study 7780297 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling without node-link mapping
Number of subjects: 0
Study 3169959 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of zinc sulphate orally thrice a day for one month
Number of subjects: 10
Study 3169959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31704093 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased compression factor (ICF, 1.75 D)
Number of subjects: 25
Study 31704093 — intervention group
Group type: COMPARATOR
Intervention: Conventional compression factor (CCF, 0.75 D)
Number of subjects: 25
Study 31015581 — intervention group
Group type: EXPERIMENTAL
Intervention: Most productive fields
Number of subjects: 350
Study 31015581 — intervention group
Group type: COMPARATOR
Intervention: Least productive fields
Number of subjects: 350
Study 31015581 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil type and crop type
Number of subjects: 350
Study 28150976 — intervention group
Group type: EXPERIMENTAL
Intervention: Yes/No questions about clothing placement
Number of subjects: 97
Study 28150976 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-choice questions about clothing placement
Number of subjects: 97
Study 28150976 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-choice questions about clothing placement
Number of subjects: 97
Study 28150976 — intervention group
Group type: EXPERIMENTAL
Intervention: Where questions about clothing placement
Number of subjects: 97
Study 28150976 — intervention group
Group type: EXPERIMENTAL
Intervention: Task using stickers and boxes
Number of subjects: 97
Study 25864752 — intervention group
Group type: EXPERIMENTAL
Intervention: Persimmon leaf extract
Number of subjects: 60
Study 25864752 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba extract
Number of subjects: 60
Study 23332667 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) group
Number of subjects: 46
Study 23332667 — intervention group
Group type: COMPARATOR
Intervention: Normal birth weight (NBW) group
Number of subjects: 46
Study 21478756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 0.14 mg/kg (part 1)
Number of subjects: 28
Study 21478756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 0.5 mg/kg (part 2)
Number of subjects: 28
Study 21478756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 1 mg/kg (part 2)
Number of subjects: 28
Study 21478756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (0.14 mg/kg, 0.5 mg/kg, 1 mg/kg)
Number of subjects: 28
Study 19646017 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fr silicon drain with an internal lumen and side holes (intraluminal stent group)
Number of subjects: 21
Study 19646017 — intervention group
Group type: COMPARATOR
Intervention: 10‐Fr silicon drain with channels along the sides (channel stent group)
Number of subjects: 21
Study 18257356 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 80
Study 18257356 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 15560155 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon (320 mg/day for 3, 6, and 12 months)
Number of subjects: 49
Study 15560155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no permixon)
Number of subjects: 49
Study 11119183 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-meds
Number of subjects: 181
Study 11119183 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-therapy
Number of subjects: 181
Study 11119183 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181
Study 9070519 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirudin (Revasc, CGP 39393); 15 mg two times a day, administered subcutaneously for 8-11 days.
Number of subjects: 445
Study 9070519 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin; 5000 international units three times a day, administered subcutaneously for 8-11 days.
Number of subjects: 445
Study 8379169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail-group received 100 ml of a homogenous fluorescein dilution
Number of subjects: 10
Study 8379169 — intervention group
Group type: COMPARATOR
Intervention: Fraction-group received 45 ml of unstained solution followed by 10 ml of concentrated dye
Number of subjects: 10
Study 3723496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg TID
Number of subjects: 39
Study 3723496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29519156 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional-training
Number of subjects: 3
Study 29519156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 29519156 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study 29352578 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led group exercise and education program for preventing recurrence of low back pain (LBP) over 8 weeks.
Number of subjects: 12
Study 29352578 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 12
Study 26821532 — intervention group
Group type: EXPERIMENTAL
Intervention: ISTp‐AL
Number of subjects: 988
Study 26821532 — intervention group
Group type: COMPARATOR
Intervention: IPTp‐SP
Number of subjects: 988
Study 26821532 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental malaria
Number of subjects: 988
Study 26821532 — intervention group
Group type: COMPARATOR
Intervention: No placental malaria
Number of subjects: 988
Study 23521782 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance spectrophotometry measurements
Number of subjects: 78
Study 23521782 — intervention group
Group type: COMPARATOR
Intervention: Conventional finger-press test
Number of subjects: 78
Study 23327695 — intervention group
Group type: EXPERIMENTAL
Intervention: Large dose of continuous veno-venous hemodiafiltration (CVVHDF) (70 ml×kg(‐1)×h(‐1), n = 9)
Number of subjects: 28
Study 23327695 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of CVVHDF (45 ml×kg(‐1)×h(‐1), n = 8)
Number of subjects: 28
Study 23327695 — intervention group
Group type: COMPARATOR
Intervention: Low dose of CVVHDF (25 ml×kg(‐1)×h(‐1), n = 11)
Number of subjects: 28
Study 20026597 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg dose of monovalent, unadjuvanted 2009 influenza A(H1N1) vaccine
Number of subjects: 370
Study 20026597 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg dose of monovalent, unadjuvanted 2009 influenza A(H1N1) vaccine
Number of subjects: 370
Study 18836047 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft hip protectors
Number of subjects: 1236
Study 18836047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard hip protectors
Number of subjects: 1236
Study 18836047 — intervention group
Group type: COMPARATOR
Intervention: Unprotected falls
Number of subjects: 1236
Study 15877214 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy
Number of subjects: 0
Study 12945073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin (30 mg mupirocin calcium hydrate ointment topically to each nostril three times a day for 3 days before operation)
Number of subjects: 395
Study 12945073 — intervention group
Group type: COMPARATOR
Intervention: Control (no mupirocin treatment)
Number of subjects: 395
Study 11220448 — intervention group
Group type: EXPERIMENTAL
Intervention: BAS-mediated mechanism
Number of subjects: 0
Study 11220448 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-mediated mechanism
Number of subjects: 0
Study 9368506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally every 6 h)
Number of subjects: 13
Study 9368506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8248954 — intervention group
Group type: EXPERIMENTAL
Intervention: colestipol/niacin plus diet therapy
Number of subjects: 188
Study 8248954 — intervention group
Group type: COMPARATOR
Intervention: placebo plus diet therapy
Number of subjects: 188
Study 3795263 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-influences resistance training
Number of subjects: 0
Study 3795263 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 0
Study 3795263 — intervention group
Group type: COMPARATOR
Intervention: Social-influences resistance training and Health education
Number of subjects: 0
Study 3795263 — intervention group
Group type: COMPARATOR
Intervention: Peer leaders and familiar media models
Number of subjects: 0
Study 30183874 — intervention group
Group type: EXPERIMENTAL
Intervention: Board game as educational technology (intervention group)
Number of subjects: 99
Study 30183874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study 27754722 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (1,500 mg p.o. daily)
Number of subjects: 30
Study 27754722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23790343 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-midvastus approach (mMV)
Number of subjects: 40
Study 23790343 — intervention group
Group type: COMPARATOR
Intervention: mini-medial parapatellar approach (mMPP)
Number of subjects: 40
Study 23790343 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical outcomes
Number of subjects: 40
Study 23014487 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified whole wheat flour (6 mg of Fe)
Number of subjects: 401
Study 23014487 — intervention group
Group type: COMPARATOR
Intervention: Control meal (unfortified)
Number of subjects: 401
Study 20075323 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic intervention (child savings accounts, workshops, mentorship)
Number of subjects: 260
Study 20075323 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional care and support services: counseling and school supplies)
Number of subjects: 260
Study 18948800 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation therapy with individual counseling and nicotine substitution starting 4 weeks before surgery and continuing 4 weeks postoperatively.
Number of subjects: 117
Study 18948800 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 117
Study 18948800 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation therapy (abstainers).
Number of subjects: 117
Study 15781813 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.3 mg
Number of subjects: 209
Study 15781813 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.3 mg (subgroup with at least one active lesion at baseline)
Number of subjects: 209
Study 15781813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 11813128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal surgery for myelomeningocele
Number of subjects: 77
Study 9778752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cold-adapted influenza A (H3N2) and trivalent inactivated influenza vaccine
Number of subjects: 100
Study 9778752 — intervention group
Group type: COMPARATOR
Intervention: Inactivated vaccine alone
Number of subjects: 100
Study 7880088 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal A and C polysaccharide vaccine
Number of subjects: 1168
Study 3418730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (15% of calories as fat)
Number of subjects: 295
Study 3418730 — intervention group
Group type: COMPARATOR
Intervention: Balanced diet (36% of calories as fat)
Number of subjects: 295